Accuracy of Magnetically Maneuvered Capsule Endoscopy for Detection of EGV in Patients With Cirrhosis

Liver Cirrhosis Clinical Trial

Official title:

Accuracy of Magnetically Maneuvered Capsule Endoscopy for Detection of Esophagogastric Varices in Patients With Cirrhosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03748563
• Other study ID #: CENTERS
• Status: Completed
• Phase: N/A
• Start date: January 7, 2021
• Est. completion date: March 6, 2023

Study information

• Verified date: July 2023
• Source: Changhai Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a diagnostic accuracy study. Eligible individuals will be enrolled and asked to undergo ds-MCE and EGD examinations. EGD is the reference standard against which ds-MCE is compared, and it will be performed within 48 hours after ds-MCE examination. The primary outcome is the sensitivity and specificity of ds-MCE in identifying the presence of esophagogastric (EGV) in patients with cirrhosis, using detection by EGD as the reference. The diagnostic accuracy of ds-MCE in detection of high-risk EV, high-risk EGV, EV, large EV, red signs of EV, GV, cardiofundal GV and PHG compared with the EGD will also be assessed. The incidence of PHE in small bowel under ds-MCE, the examination time of ds-MCE and EGD procedures, patient satisfaction assessment and safety evaluation will also be evaluated.

Description:

Cirrhosis is the major cause of liver disease-related morbidity and mortality worldwide. Portal hypertension (PH) is the hemodynamic abnormality in patients with cirrhosis, which is associated with various pathological changes throughout the entire gastrointestinal tract, manifesting as esophagogastric varices (EGV), portal hypertensive gastropathy (PHG), and portal hypertensive enteropathy (PHE). Baveno consensus and other practice guidelines recommended that patients with cirrhosis undergo endoscopic screening for EGV at the time of diagnosis and undergo periodic surveillance endoscopy throughout the whole course of cirrhosis.

Esophagogastroduodenoscopy (EGD) is recognized as the gold standard for detection and follow-up of EGV in cirrhotic patients, allowing for direct mucosal visualization and therapeutic intervention. EGD is however an invasive procedure and there is potential for procedure-related complications, such as perforation and bleeding. Besides, conscious sedation is always required, leading to increased cost, risk, and inconvenience for the patients.These factors lead to a decrease of patient compliance as well as the effectiveness of the screening program.

The capsule endoscopy (CE) system provides a noninvasive and relatively comfortable approach to visualize the GI tract, and the development of esophageal capsule endoscopy (ECE) makes it possible to capture clear images of esophagus without the need of sedation. However, the accuracy of ECE is not currently sufficient to replace EGD for the detection and grading for the esophageal varices. Besides, previous studies presented that the sensitivity of ECE for detecting gastric varices (GVs) and PHG varies from 3% to 69%, which denoted ECE was far from a suitable alternative for diagnosing gastric lesions.

To overcome these limitations, a new technique, so-called detachable string magnetically maneuvered capsule endoscopy (ds-MCE) was developed. The ds-MCE system consists of two parts: the magnetically maneuvered capsule endoscopy (MCE) system and a transparent latex sleeve with a hollow string. One end of the hollow string is a transparent thin latex sleeve that can be wrapped on the surface of the capsule, and the other end of the string is connected to the syringe. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. In this case, investigator can examine the entire esophageal mucosa several times under real time views. The capsule then can be detached from the string system through injecting air into the hollow string with the syringe after completing the examination of esophagus. The magnetic capsule in the stomach can be accurately controlled through multidimensional rotation and adaptive matching of an external C-arm robot. Previous studies have demonstrated that the diagnostic accuracy of MCE for detecting gastric focal lesions is comparable with that of conventional EGD. Two previously studies of ds-MCE confirmed it was a feasible, safe and well-tolerated method for completely viewing esophagus and stomach, without the need for sedation. Besides, the 8-10h battery life of the ds-MCE enables complete examination of the small bowel, which enables to provide a more comprehensive evaluation of gastrointestinal changes.

Considering all these backgrounds, in the current prospective study, the primary aim is to assess the diagnostic performance of the ds-MCE in identifying the presence of EGV in cirrhotic patients, using EGD as the reference standard. The diagnostic accuracy of ds-MCE in detection of high-risk EV, high-risk EGV, EV, large EV, red signs of EV, GV, cardiofundal GV and PHG compared with the EGD will also be assessed. The incidence of PHE in small bowel under ds-MCE, the examination time of ds-MCE and EGD procedures, patient satisfaction assessment and safety evaluation will also be evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 607
• Est. completion date: March 6, 2023
• Est. primary completion date: January 10, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Gender is not limited.

2. Patients aged 18 years or older.

3. Both inpatients and outpatients.

4. Clinically evident or biopsy-proven liver cirrhosis.

5. Able to provide informed consent.

Exclusion Criteria:

1. Patients aged less than 18 years.

2. Patients with Zenker's diverticulum.

3. Patients with active gastrointestinal bleeding.

4. Patients who have participated in or are participating in other clinical trials.

5. Pregnancy or suspected pregnancy.

6. Suspected or known intestinal stenosis or other known risk factors for capsule retention.

7. Pacemaker or other implanted electromedical devices which could interfere with magnetic resonance.

8. Patients with dysphagia.

9. Life-threatening conditions.

10. Patients plan to undergo magnetic resonance imaging examination before excretion of the MCE.

11. Patients who refuse to give informed consent.

12. Patients with any condition that precludes compliance with the study.

Related Conditions & MeSH terms

• Esophageal and Gastric Varices
• Esophageal Varices
• Fibrosis
• Gastric Varix
• Hypertension, Portal
• Liver Cirrhosis
• Portal Hypertension
• Varicose Veins

Intervention

Diagnostic Test:
• ds-MCE and EGD
Procedure of ds-MCE: The ds-MCE system mainly consists of two parts: the NaviCam magnetically maneuvered capsule endoscopy system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. After completing the esophageal examination, the capsule could be detached from the string through injecting air into the hollow string with the syringe. Then, the examination of stomach under magnetic control and small bowel under the natural action of gastrointestinal peristalsis follows. Procedure of EGD: The esophagogastroduodenoscopy (EGD) will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session.

Locations

Country	Name	City	State
China	The Third Xiangya Hospital of Central South University	Changsha	Hunan
China	Zhujiang Hospital,Southern Medical University	Guangzhou	Guangdong
China	The First Affiliated Hospital of Zhejiang Chinese Medical University	Hanzhou	Zhejiang
China	Qilu Hospital of Shandong University	Jinan	Shandong
China	Changhai Hospital	Shanghai
China	Ruijin Hospital	Shanghai	Shanghai
China	Shanghai East Hospital, Tongji University School of Medicine	Shanghai	Shanghai
China	Shanghai Jiao Tong University affiliated Sixth people's Hospital	Shanghai	Shanghai
China	Shanghai Pudong New Area Gongli Hospital	Shanghai	Shanghai
China	Shanghai Tongji Hospital, Tongji University School of Medicine	Shanghai	Shanghai
China	Yangpu District Central Hospital Affiliated to Tongji University	Shanghai	Shanghai
China	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	Hubei
China	First Affiliated Hospital Xi'an Jiaotong University	Xi'an	Shanxi
China	the Fifth Affiliated Hospital of Zunyi Medical University	Zhuhai	Guangdong

Sponsors (14)

Lead Sponsor

Collaborator

Changhai Hospital

First Affiliated Hospital Xi'an Jiaotong University, Qilu Hospital of Shandong University, Ruijin Hospital, Shanghai East Hospital of Tongji University, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Pudong New Area Gongli Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, The Fifth Affiliated Hospital of Zunyi Medical College, The First Affiliated Hospital of Zhejiang Chinese Medical University, The Third Xiangya Hospital of Central South University, Wuhan Union Hospital, China, Yangpu District Central Hospital Affiliated to Tongji University, Zhujiang Hospital

Country where clinical trial is conducted

China, 

References & Publications (10)

D'Amico G, De Franchis R; Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003 Sep;38(3):599-612. doi: 10.1053/jhep.2003.50385. — View Citation

de Franchis R, Eisen GM, Laine L, Fernandez-Urien I, Herrerias JM, Brown RD, Fisher L, Vargas HE, Vargo J, Thompson J, Eliakim R. Esophageal capsule endoscopy for screening and surveillance of esophageal varices in patients with portal hypertension. Hepatology. 2008 May;47(5):1595-603. doi: 10.1002/hep.22227. — View Citation

de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022. Epub 2015 Jun 3. No abstract available. — View Citation

Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007 Sep;46(3):922-38. doi: 10.1002/hep.21907. No abstract available. Erratum In: Hepatology. 2007 Dec;46(6):2052. — View Citation

Gralnek IM, Adler SN, Yassin K, Koslowsky B, Metzger Y, Eliakim R. Detecting esophageal disease with second-generation capsule endoscopy: initial evaluation of the PillCam ESO 2. Endoscopy. 2008 Apr;40(4):275-9. doi: 10.1055/s-2007-995645. — View Citation

Kodama M, Uto H, Numata M, Hori T, Murayama T, Sasaki F, Tsubouchi N, Ido A, Shimoda K, Tsubouchi H. Endoscopic characterization of the small bowel in patients with portal hypertension evaluated by double balloon endoscopy. J Gastroenterol. 2008;43(8):589-96. doi: 10.1007/s00535-008-2198-1. Epub 2008 Aug 17. — View Citation

Lapalus MG, Dumortier J, Fumex F, Roman S, Lot M, Prost B, Mion F, Ponchon T. Esophageal capsule endoscopy versus esophagogastroduodenoscopy for evaluating portal hypertension: a prospective comparative study of performance and tolerance. Endoscopy. 2006 Jan;38(1):36-41. doi: 10.1055/s-2006-924975. — View Citation

North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med. 1988 Oct 13;319(15):983-9. doi: 10.1056/NEJM198810133191505. — View Citation

Sarin SK, Lahoti D, Saxena SP, Murthy NS, Makwana UK. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology. 1992 Dec;16(6):1343-9. doi: 10.1002/hep.1840160607. — View Citation

Spina GP, Arcidiacono R, Bosch J, Pagliaro L, Burroughs AK, Santambrogio R, Rossi A. Gastric endoscopic features in portal hypertension: final report of a consensus conference, Milan, Italy, September 19, 1992. J Hepatol. 1994 Sep;21(3):461-7. doi: 10.1016/s0168-8278(05)80329-0. No abstract available. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the diagnostic accuracy of the ds-MCE in identifying the presence of esophagogastric varices (EGV)	the sensitivity and specificity of ds-MCE in identifying EGV in patients with cirrhosis, using the detection by EGD as the reference.	2 weeks
Secondary	the diagnostic accuracy of the ds-MCE in identifying the presence of esophageal varices (EV)	The sensitivity, specificity, PPV, NPV and overall diagnostic accuracy of ds-MCE in detection of EV, using the detection by EGD as the reference.	2 weeks
Secondary	the diagnostic accuracy of the ds-MCE in identifying the red sign of EV	The sensitivity, specificity, PPV, NPV and overall diagnostic accuracy of ds-MCE in identifying the red sign of EV, using the detection by EGD as the reference.	2 weeks
Secondary	the diagnostic accuracy of the ds-MCE in differentiating large esophageal varices	The sensitivity, specificity, PPV, NPV and overall diagnostic accuracy of ds-MCE in detection of large EV, using the detection by EGD as the reference.	2 weeks
Secondary	the optimal esophageal luminal circumference percentage threshold under ds-MCE for distinguishing large EV	To investigate the optimal threshold of the proportion of ds-MCE esophageal luminal circumference occupied by the largest esophageal varix present in differentiating large EV from small or no EV, using the detection by EGD as the reference.	2 weeks
Secondary	the diagnostic accuracy of the ds-MCE in differentiating high-risk esophageal varices	The sensitivity, specificity, PPV, NPV and overall diagnostic accuracy of ds-MCE in detection of high-risk EV, using the detection by EGD as the reference.	2 weeks
Secondary	the diagnostic accuracy of the ds-MCE in detection of high-risk EGV	The sensitivity, specificity, PPV, NPV and overall diagnostic accuracy of ds-MCE in detection of high-risk EGV, using the detection by EGD as the reference.	2 weeks
Secondary	the diagnostic accuracy of the ds-MCE in detecting gastric varices (GV)	The sensitivity, specificity, PPV, NPV and overall diagnostic accuracy of ds-MCE in detection of GV, using the detection by EGD as the reference.	2 weeks
Secondary	the diagnostic accuracy of the ds-MCE in detecting cardiofundal gastric varices	The sensitivity, specificity, PPV, NPV and overall diagnostic accuracy of ds-MCE in detection of cardiofundal GV, using the detection by EGD as the reference.	2 weeks
Secondary	the diagnostic accuracy of the ds-MCE in identifying portal hypertensive gastropathy	The sensitivity, specificity, PPV, NPV and overall diagnostic accuracy of ds-MCE in detection of portal hypertensive gastropathy (PHG), using the detection by EGD as the reference.	2 weeks
Secondary	the incidence of portal hypertensive enteropathy (PHE) under ds-MCE	Endoscopic findings of PHE include mucosal inflammatory-like abnormalities, vascular lesions and spontaneous bleeding.	2 weeks
Secondary	the examination time of ds-MCE and EGD	Examination time of ds-MCE include esophageal transit time (ETT), gastric examination time (GET), gastric transit time (GTT), small bowel transit time (SBTT), and total running time (TRT). Examination time of EGD is the time from the endoscope entering to exiting from the esophagus.	2 weeks
Secondary	patient satisfaction evaluation of the ds-MCE and EGD	Patient satisfaction score of ds-MCE and EGD procedures.	2 weeks
Secondary	Safety evaluation	All adverse events occurring during the study will be recorded.	2 weeks